Open AccessInteraction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
Author(s) -
Wilcox Christopher S.,
Shen Wen,
Boulton David W.,
Leslie Bruce R.,
Griffen Steven C.
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007046
Subject(s) - dapagliflozin , bumetanide , diuretic , endocrinology , medicine , excretion , loop diuretic , diuresis , distal convoluted tubule , cotransporter , sodium , reabsorption , renal function , pharmacology , chemistry , diabetes mellitus , kidney , type 2 diabetes , organic chemistry
Dapagliflozin inhibits the sodium-glucose-linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium-glucose-linked transporter 2 inhibition causes an osmotic diuresis, we evaluated the diuretic interaction between dapagliflozin and bumetanide.